Medication Monitor



Generic Name (Trade Name—Company)
Notes
May 23, 2011

Telaprevir

(Incivek—Vertex)
Second agent approved for hepatitis C virus infections

Uses:

Treatment of chronic hepatitis C genotype 1 infection

Telaprevir is another oral agent approved by FDA for the treatment of chronic hepatitis C genotype 1 infection in adult patients with compensated liver disease, including those with cirrhosis. As with boceprevir, it must be given in combination with peginterferon alfa and ribavirin and can be used in patients who are previously untreated or those who have failed previous interferon and ribavirin therapy. Telaprevir’s mechanism of action is identical to boceprevir. The recommended dose is 750 mg (two 375-mg tablets) given orally three times daily (approximately every 7 to 9 hours) with food. It is given in combination with peginterferon alfa and ribavirin for the first 12 weeks. When added to peginterferon alfa and ribavirin, sustained viral response rates was as high as 79% in trials.